DAX20.642 -5,0%ESt504.878 -4,6%Top 10 Crypto11,23 +2,3%Dow38.315 -5,5%Nas15.588 -5,8%Bitcoin75.762 -1,0%Euro1,0961 ±-0,0%Öl66,06 -5,4%Gold3.038 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 Apple 865985 Amazon 906866 Allianz 840400 Mercedes-Benz Group (ex Daimler) 710000 RENK RENK73 Lufthansa 823212 Infineon 623100 Microsoft 870747 BASF BASF11 Deutsche Bank 514000 Volkswagen (VW) vz. 766403 Nike 866993
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Zölle: China schlägt zurück -- DAX geht massiv tiefer ins Wochenende -- Wall Street stürzt letztlich ab -- Aktien von Rheinmetall, RENK & HENSOLDT im Minus -- Novo Nordisk, Apple im Fokus
Top News
Branchenrotation - Durch Branchenkenntnis Überrenditen erzielen Branchenrotation - Durch Branchenkenntnis Überrenditen erzielen
Bitcoin, Dogecoin, Ethereum & Co. am Nachmittag Bitcoin, Dogecoin, Ethereum & Co. am Nachmittag
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Bis zu 3,05 % Zinsen: Jetzt die besten Tagesgeld-Angebote checken

Eli Lilly Aktie

NeuKaufenVerkaufen
Eli Lilly Aktien-Sparplan
673,40 EUR -41,70 EUR -5,83 %
STU
717,50 USD -21,10 USD -2,86 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.638,46 Mrd. EUR

KGV65,91Div. Rendite0,67%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN858560

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS5324571083

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLLY

Eli Lilly Aktien News

DatumMeistgelesen
EN, Eli LillyStatement: Lilly has no affiliation with hims & hers
EN, Eli LillyLilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
PR NewswireLilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
Wer­bungEli Lilly-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
EN, Eli LillyLilly’s statement about the CHMP opinion issued for donanemab
EN, Eli LillyLillyDirect platform expands to facilitate access to Alzheimer's disease care
PR NewswireLillyDirect platform expands to facilitate access to Alzheimer's disease care
EN, Eli LillyLilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
PR NewswireLilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
PR NewswireLilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
EN, Eli LillyLilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
PR NewswireLilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
EN, Eli LillyLilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
PR NewswireLilly to participate in Leerink Partners Global Healthcare Conference
EN, Eli LillyLilly to participate in Leerink Partners Global Healthcare Conference
PR NewswireLilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhi...
PR NewswireLilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion
EN, Eli LillyLilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion
EN, Eli LillyLilly launches additional Zepbound vial doses and offers new savings for self-pay patients
PR NewswireLilly launches additional Zepbound vial doses and offers new savings for self-pay patients
PR NewswireLilly to participate in TD Cowen's 45th Annual Health Care Conference
EN, Eli LillyLilly to participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
EN, Eli LillyMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
EN, Eli LillyMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
EN, Eli LillyLilly reports full Q4 2024 financial results and provides 2025 guidance
PR NewswireLilly reports full Q4 2024 financial results and provides 2025 guidance
PR NewswireLilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
EN, Eli LillyLilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
EN, Eli LillyFDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
PR NewswireFDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
PR NewswireLilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
EN, Eli LillyLilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
PR NewswireLilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
EN, Eli LillyLilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
PR NewswireLilly to participate in J.P. Morgan Healthcare Conference
EN, Eli LillyLilly to participate in J.P. Morgan Healthcare Conference
EN, Eli LillyLilly commends ITC ruling cracking down on the unlawful importation and sale of knock-off tirzepatide products that put Americans at risk
EN, Eli LillyFDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
PR NewswireFDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
PR NewswireLilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Wer­bung

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.